AstraZeneca’s Farxiga (dapagliflozin) has met the primary endpoint in Phase III DAPA-HF study involving patients with reduced ejection fraction (HFrEF), with or without type 2 diabetes.

Compared to placebo, the drug showed a statistically-significant and clinically-meaningful decrease in cardiovascular death or the worsening of heart failure when given in addition to standard of care.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The safety profile of the drug was also observed to be consistent with its established profile.

AstraZeneca BioPharmaceuticals R&D executive vice-president Mene Pangalos said: “With the DAPA-HF trial, Farxiga becomes the first in its class to demonstrate efficacy and safety data for the treatment of patients with heart failure, with and without type 2 diabetes, on top of standard of care.

“Today, half of heart failure patients will die within five years of diagnosis and it remains one of the leading causes of hospitalisation. We look forward to discussing the results of DAPA-HF with health authorities as soon as possible.”

Farxiga is an oral, once-daily sodium-glucose transport protein 2 (SGLT2) inhibitor being developed as a single agent and combination therapy to improve glycaemic control.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In adjunction with diet and exercise, the drug also helps in weight loss and blood-pressure reduction in type 2 diabetes patients.

The international, multi-centre, parallel-group, randomised, double-blind DAPA-HF study assessed a 10mg dose of the drug.

It is said to be the first heart failure trial to investigate an SGLT2 inhibitor given in addition to standard of care in subjects with and without type-2 diabetes.

DAPA-HF forms part of the DapaCare clinical programme designed to study Farxiga’s cardiovascular (CV) and renal profile in approximately 30,000 patients with and without type-2 diabetes.

The drug is also being evaluated in heart failure patients participating in the DELIVER and DETERMINE studies, as well as in chronic kidney disease patients in the DAPA-CKD trial.